Effects of anethum graveolens and garlic on lipid profile in hyperlipidemic patients

Abstract

Effects of anethum graveolens and garlic on lipid profile in hyperlipidemic patients

Javad Kojuri, Amir R Vosoughi and Majid Akrami

Department of Cardiology, Shiraz University of Medical Sciences, Shiraz, Iran

Background

hyperlipidemia as a major risk factor of atherosclerosis is treated with different drugs. Concerning length of therapy and vast majority of side effects, herbal medication may be suitable substitute for these drugs.

Methods

In this single-blind, placebo controlled study, lipid profiles of 150 hyperlipidemic patients in cardiology outpatient department of Shiraz University of Medical Sciences were checked at same conditions. They were divided into three equal groups randomly (each composing of 50 patients). They were given enteric-coated garlic powder tablet (equal to 400 mg garlic, 1 mg allicin) twice daily, anethum tablet (650 mg) twice daily, and placebo tablet. All patients were put on NCEP type Π diet and Six weeks later, lipid profiles were checked.

Results

In garlic group: total cholesterol (decreased by 26.82 mg/dl, 12.1% reduction, and P-value: .000), and LDL-cholesterol (decreased by 22.18 mg/dl, 17.3% reduction, and P-value: .000) dropped. HDL-cholesterol (increased by 10.02 mg/dl, 15.7% increase, and P-value: .000) increased. Although triglyceride dropped by 13.72 mg/dl (6.3%) but this was not significant statistically (P-value: .222). In anethum group: surprisingly, triglyceride increased by 14.74 mg/dl (6.0%). Anethum could reduce total cholesterol by 0.4 % and LDL-cholesterol by 6.3% but these were not significant statistically (P-value: .828, and .210, respectively).

Conclusion

Anethum has no significant effect on lipid profile, but garlic tablet has significant favorable effect on cholesterol, LDL-cholesterol, and HDL-cholesterol. Garlic may play an important role in therapy of hypercholesterolemia.

Lipids in Health and Disease 2007, 6:5. This is an Open Access article distributed under the terms of the Creative Commons Attribution License.


Background

Atherosclerosis remains the major cause of death and premature disability. Hyperlipidemia is the most firmly established and best understood risk factor for atherosclerosis [1]. Nowadays, major drugs used for treatment of hyperlipidemia have several adverse effects. Herbal medications such as Garlic (Allium sativum) and Anethum graveolens are prescribed as antihyperlipidemic agents.

The medicinal uses of garlic have a long history [2]. Recent studies have validated many of its useful properties, such as:

• Cancer-preventive actions [3-5]

• Stimulation of phagocytotic function of macrophages and lymphocyte proliferation [6]

Antimicrobial effects. In vitro, allicin, the main organosulfur compound of garlic, has demonstrated activity against gram-positive and gram-negative bacteria as well as fungi, protozoa, and certain viruses [7].

• The cardiovascular-protective effects of garlic have been evaluated extensively in recent years. In animal experiments, garlic extracts have been shown to lower plasma lipid and cholesterol in rats [[8,9], and [10]], rabbits [11], chickens [12], and swine [13]. Moreover, a number of intervention studies have similarly shown that garlic significantly reduced plasma lipids, especially total cholesterol and Low Density Lipoprotein (LDL) cholesterol in humans [[14,15], and [16]]. Aside from the reported antiplatelet aggregation and antithrombotic action [17], garlic reduced blood pressure [[18,19], and [20]] and stimulated fibrinolytic activity [21,23]. It was reviewed that aged garlic extract contains antioxidant compounds and increase nitric oxide production and decreases the output of inflammatory cytokines from cultured cells. These data suggest that garlic may improve impaired endothelial function in men with coronary disease treated with aspirin and statin [22]. Two meta-analyses of randomized, placebo-controlled human studies confirmed the hypocholesterolemic effects of garlic [24,25]. The analyses further detected that the extent of the cholesterol-lowering properties of garlic differed markedly from one study to another [24,25]. It was estimated from the five randomized clinical trials that hypercholesterolemic patients treated with garlic had a mean plasma cholesterol concentration that was 9% lower than that of patients treated with placebo [25]. Silagy and Neil [25], on the other hand, concluded from the analysis of 17 human studies that plasma cholesterol concentrations of the subjects treated with garlic were 12% lower than those receiving placebo. Furthermore, the two analyses detected a wide range of decrease in mean plasma cholesterol concentrations (i.e., 6–53 mg/dl) among the studies. However, garlic supplementation has been shown not to decrease plasma cholesterol concentrations in human [[26,27], and [28]]. Although the reasons for the inconsistent observations are not readily apparent, it is worthwhile to note that garlic contains a variety of organosulfur compounds, amino acids, vitamins and minerals [2]. Some of the sulfur compounds such as allicin, ajoene, S-allylycysteine (SAC), diallyl disulfide (DADS), S-methylcysteine sulfoxide, and S-allylcysteine sulfoxide may be responsible for the therapeutic properties of garlic [9]. Animal studies have shown that garlic supplementation in the diet depressed the hepatic activities of lipogenic and cholesterogenic enzymes such as 3-hydroxy-3-methyl-glutaryl-CoA(HMG-CoA) reductase [29].

Anethum graveolens is another herbal medication with antihyperlipidemic effects. Administration of water extract of anethum graveolens leaves for 14 days can reduce triglyceride and total cholesterol levels by almost 50 % and 20 %, respectively [30].

Nowadays, there is wide spread belief among general public that garlic and anethum graveolens have beneficial effects on hyperlipidemia. This belief persuaded us to perform this investigation.


Materials and methods

A single-blind, randomized, placebo-controlled intervention study was conducted on patients with coronary artery disease with newly diagnosed hyperlipidemia. One hundred and seventy two patients were selected from cardiology outpatient department of Shiraz University of Medical Sciences. Exclusion criteria included; having significant hepatic, renal and gastrointestinal tract disease, acute myocardial infarction, uncontrolled endocrine disease, and underlying previous therapies for hyperlipidemia. Twenty two cases were excluded. One hundred and fifty patients had total cholesterol level ≥ 200 mg/dl and/or LDL-cholesterol ≥ 100 mg/dl after 10 hours of fasting with standard enzymatic methods. Also, we checked HDL-cholesterol and triglyceride. Written informed consent was obtained from each patient before any study-specific procedure.

We randomly divided patients into three groups, each composing of 50 cases. Garlic group received enteric-coated garlic powder tablet (equal to 400 mg garlic and 1 mg allicin) twice daily. Patients of Anethum group were prescribed anethum tablet 650 mg twice daily. Placebo group were given placebo. Demographic information of different groups is in table 1. After 6 weeks, we checked total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglyceride after 10 hours of fasting.

All patients were given NCEP type Π, i.e. protein about 0.6 g/kg desirable body weight per day, 55 % of total calories from carbohydrate, no more than 30 % of total energy intake be derived from dietary fat, polyunsaturated fats to

Data were analyzed by paired sample t test and non parameter 2 related sample test using SPSS 13.0 program for windows (SPSS Inc. Chicago, Illinois). A difference was considered statistically significant when the probability value (P-value) was


Results

Fortunately, all of the patients cooperated well and did not show any adverse effect of these herbal drugs.

Changes of lipid profiles after 6 weeks and results of paired t test are shown in table 2 and 3, respectively. It was found that changes in triglyceride, total cholesterol, LDL-cholesterol, and HDL-cholesterol were significantly different between three groups.

Placebo

Placebo could not improve lipid profile. Triglyceride, total cholesterol, and LDL-cholesterol increased and HDL-cholesterol was reduced. These changes were not meaningful (P-value > 0.05).

Anethum graveolens

Anethum didn't have any beneficial effect on triglyceride (6.0% increase) and HDL-cholesterol (3.1% reduction). It could reduce total cholesterol by 0.4 % and LDL-cholesterol by 6.3 %, but these reductions were not significant statistically (P-value: .828, .210, respectively).

Garlic

At the end of the six-week intervention period, it was fond that changes in triglyceride, total cholesterol, LDL-cholesterol, and HDL-cholesterol were significantly different from other groups. The mean total cholesterol concentration dropped in the garlic group by 26.82 mg/dl (P-value: .000.) Similarly, LDL-cholesterol was reduced in this group by 22.18 mg/dl (P-value: .000). Surprisingly, HDL-cholesterol was increased by 10.02 mg/dl (P-value: .000). Although triglyceride dropped by 13.72 mg/dl but this was not meaningful (P-value: .222).


Discussion

Garlic

Our study suggests that garlic reduces total cholesterol & LDL-cholesterol. This is similar to Alder and Holub's study (11.5% decrease of total cholesterol, and 14.2% decrease of LDL-cholesterol) [31], Tohidi and Rahbani's trial (9.0% decrease of total cholesterol, 15.0% decrease of LDL-cholesterol)[32], study of Steiner et al (6.1% decrease of total cholesterol, 4.0% decrease of LDL-cholesterol) [18]. Also, other studies explained these benefits [24,25].

HDL-cholesterol should be investigated in more clinical trials. Stevinson et al [33] in meta-analysis of randomized clinical trials on antihyperlipidemic effect of garlic explained that a slight increase in HDL-cholesterol level in the garlic group was not significantly different from the effect of placebo. Our search could corroborate garlic effect on increasing HDL-cholesterol (P-value: .000, HDL-cholesterol increased by 15.7%)

Triglyceride dropped by prescription of garlic tablet by 6.3% (13.72 mg/dl), according to Tohidi and Rahbani's study [32], and Mader's trial [34]. But due to P-value: .222, this reduction was not significant difference from the effect of placebo.

Anethum graveolens

Anethum could reduce total cholesterol and LDL-cholesterol (1.12 mg/dl and 9.34 mg/dl, respectively) but these differences were not significant (P-value: .828 and .210, respectively). Surprisingly, it reduced HDL-cholesterol (3.1%) and increased triglyceride level by 6.0%. Our study on anethum is opposite to that of Yazdanparast and Alavi [34].

In conclusion we found that enteric-coated garlic tablet can reduce total cholesterol, LDL-cholesterol and increase HDL-cholesterol, with no effect on triglyceride. On the other hand, anethum graveolens can not be an antihyperlipidemic agent.


References

  1. Libby P: Prevention and treatment of atherosclerosis.In Harrison's principles of internal medicine. McGraw Hill; 2005:1430.

  2. Block E: The chemistry of garlic and onion.

    Sci Am 1985, 252:114-119.

  3. Amagase H, Milner JA: Impact of various sources of garlic and their constituents on 7, 12-DMBA binding to mammary cell DNA.

    Carcinogenesis 1993, 14:1627-1631.

  4. Milner JA: Garlic: its anticarcinogenic and antimutagenic properties.

    Nutr Rev 1996, 54:S82-S86.

  5. Sumiyoshi H, Wargovich M: Chemoprevention of 1,2-dimethylhydrazine-induced colon cancer in mice by naturally occurring organosulfur compounds.

    Cancer Res 1990, 50:5084-5087.

  6. Tadi PP, Teel RW, Lau BHS: Anticandidal and anticarcinogenic potentials of garlic.

    Int Clin Nutr Rev 1990, 10:423-429.

  7. Dennehy CE, Tsourounis C: Biotanicals ("herbal medications") & nutritional supplements.In Basic & clinical pharmacology. McGrawHill; 2001:1092-3.

  8. Gorinstein S, Leontowicz H, Leontowicz M, Drzewiecki J, Najman K, Katrich E, Barasch D, Yamamoto K, Trakhtenberg S: Raw and boiled garlic enhances plasma antioxidant activity and improves plasma lipid metabolism in cholesterol-fed rats.

    Life Sci 2006, 78:655-663.

  9. Chi MS: Effects of garlic products on lipid metabolism in cholesterol-fed rats.

    Proc Soc Exp Biol Med 1982, 171:174-178.

  10. Saravanan G, Prakash J: Effect of garlic (Allium sativum) on lipid peroxidation in experimental myocardial infarction in rats.

    J Ethnopharmacol 2004, 94:155-158.

  11. Bordia A, Verma SK: Effect of garlic feeding on regression of experimental atherosclerosis in rabbits.

    Artery 1980, 7:428-437.

  12. Qureshi AA, Abuirmeileh N, Din ZZ, Elson CE, Burger WC: Inhibition of cholesterol and fatty acid biosynthesis in liver enzymes and chicken hepatocytes by polar fractions of garlic.

    Lipids 1983, 18:343-348.

  13. Qureshi AA, Crenshaw TD, Abuirmeileh N, Peterson DM, Elson CE: Influence of minor plant constituents on porcine hepatic lipid metabolism: impact on serum lipid.

    Atherosclerosis 1987, 64:109-115.

  14. Arora RC, Arora S: Comparative effect of clofibrate, garlic and onion on alimentary hyperlipemia.

    Atherosclerosis 1981, 39:447-452.

  15. Jain AK, Vargas R, Gotzkowsky S, McMahon FG: Can garlic reduce levels of serum lipids? A controlled clinical study.

    Am J Med 1993, 94:632-635.

  16. Yeh YY, Lin RI, Yeh SM, Evens S: Garlic reduces plasma cholesterol in hypercholesterolemic men maintaining habitual diets.In Food Factors for Cancer Prevention. Edited by: Ohigashi H. Osawa T. Terao J. Watanabe S. Toshikawa T. Springer Tokyo, Japan; 1997:226-230.

  17. Shin SH, Kim MK: Effect of dried powders or ethanol extracts of garlic flesh and peel on lipid metabolism and antithrombogenic capacity in 16-month-old rats.

    Hanguk Yongyang Hakhoechi 2004, 37:515-524.

  18. Steiner M, Khan AH, Holbert D, Lin RI: A double-blind crossover study in moderately hypercholesterolemic men that compared the effect of aged garlic extract and placebo administration on blood lipids.

    Am J Clin Nutr 1996, 64:866-870.

  19. Silagy C, Neil A: A meta-analysis of the effect of garlic on blood pressure.

    J Hypertens 1994, 12:463-468.

  20. Ernst E: Cardiovascular effects of garlic (Allium sativum): a review.

    Pharmatherapeutica 1987, 5:83-89.

  21. Jabbari A, Argani H, Ghorbanihaghjo A, Mahdavi R: comparison between swallowing and chewing of garlic on levels of serum lipid, cyclosporine, creatinine and lipid peroxidation in renal transplant recipients.

    Lipids in health and disease 2005, 4:11.

  22. Williams MJA, Sutherland WHF, McCormick MP, Yeoman DJ, de Jong SA: Aged garlic extract improves endothelial function in men with coronary artery disease.

    Phytother Res 2005, 19:314-319.

  23. Arora RC, Arora S, Gupta RK: The long-term use of garlic in ischemic heart disease-an appraisal.

    Atherosclerosis 1981, 40:175-179.

  24. Silagy C, Neil A: Garlic as a lipid lowering agent – a meta-analysis.

    J R Coll Physicians Lond 1994, 28:39-45.

  25. Warshafsky S, Kamer RS, Sivak SL: Effect of garlic on total serum cholesterol. A meta-analysis.

    Ann Intern Med 1993, 119:599-605.

  26. Simons LA, Balasubramanian S, von Konigsmark M, Parfitt A, Simons J, Peters W: On the effect of garlic on plasma lipids and lipoproteins in mild hypercholesterolemia.

    Atherosclerosis 1995, 113:219-225.

  27. Berthold HK, Sudhop T, von Bergmann K: Effect of a garlic oil preparation on serum lipoproteins and cholesterol metabolism: a randomized controlled trail.

    J Am Med Assoc 1998, 279:1900-1902.

  28. Isaacsohn JL, Moser M, Stein EA, Dudley K, Davey JA, Liskov E, Black HR: Garlic powder and plasma lipids and lipoproteins.

    Arch Intern Med 1998, 158:1189-1194.

  29. Mathew BC, Prasad NV, Prabodh R: Cholesterol-lowering effect of organosulphur compounds from garlic: a possible mechanism of action.

    Kathmandu Univ Med J 2004, 2(2):100-2.

  30. Yazdanparast R, Alavi M: Antihyperlipidemic and antihypercholesterolaemic effects of Anethum graveolens leaves after the removal of furocoumarins.

    Cytobios 2001, 105(410):185-91.

  31. Adler AJ, Holub BJ: Effect of garlic and fish-oil supplementation on serum lipid and lipoprotein concentrations in hypercholesterolemic men.

    Am J Clin Nutr 1997, 65:445-450.

  32. Tohidi M, Rahbani M: Evaluation of the effect of garlic powder on blood pressure, serum lipids and lipoproteins.

    Pharmacy journal of Tabriz Univ Med Sci 2000, 4:16-20.

  33. Stevinson C, Pittler MH, Ernst E: Garlic for treating hypercholesterolemia (a meta-analysis of randomized clinical trials).

    Ann Intern Med 2000, 133:420-429.

  34. Mader FH: Treatment of hyperlipidemia with garlic-powder tablets: evidence from the German Association of General Practitioner's multicentric placebo-controlled double-blind study.

    Arzneimittel Forschung Drug Re 1990, 40:3-8.


Tables

Table 1

Demographic characteristics of different groups


Garlic group
Anethum group
Placebo group
Total
Numbers
50
50
50
150
     Female
32
33
30
95
     Male
18
17
20
55
Age (year)




     Mean
55
55.56
56.5
55.8
     Minimum
39
31
39
31
     Maximum
78
75
74
78

Kojuri et al. Lipids in Health and Disease 2007 6:5   doi:10.1186/1476-511X-6-5

 

Table 2

Changes in lipid profile after 6 weeks


Garlic
Anethum
Placebo

Mg/dl
percent
Mg/dl
percent
Mg/dl
percent
Triglyceride
↓ 13.72
↓ 6.3
↑ 14.74
↑ 6.0
↑ 4.44
↑ 2.0
T C
↓ 26.82
↓ 12.1
↓ 1.12
↓ 0.4
↑ 4.6
↑ 2.0
LDL
↓ 22.18
↓ 17.3
↓ 9.34
↓ 6.3
↑ 2.3
↑ 1.6
HDL
↑ 10.02
↑ 15.7
↓ 1.4
↓ 3.1
↓ 2.14
↓ 4.6

T C: Total Cholesterol, LDL: Low Density Lipoprotein Cholesterol, HDL: High Density Lipoprotein Cholesterol

Kojuri et al. Lipids in Health and Disease 2007 6:5   doi:10.1186/1476-511X-6-5

Table 3

Results of paired t test in different groups.


mean
Standard deviation
95% confidence interval of the difference
t
P-value



Lower
Upper


Garlic






     TG1 – TG2
13.72
78.38
-8.56
36.00
1.238
0.222
     TC1 – TC2
26.82
33.61
17.27
36.37
5.642
0.000
     LDL1–LDL2
22.18
31.91
13.11
31.25
4.915
0.000
     HDL1–HDL2
-10.02
10.55
-13.02
-7.02
-6.715
0.000
Anethum






     TG1 – TG2
-14.74
73.59
-35.65
6.17
-1.416
0.163
     TC1 – TC2
1.12
36.24
-9.18
11.42
0.219
0.828
     LDL1–LDL2
9.34
51.96
-5.43
24.11
1.271
0.210
     HDL1–HDL2
1.42
10.30
-1.51
4.35
0.975
0.334
Placebo






     TG1 – TG2
-4.44
30.66
-13.15
4.27
-1.024
0.311
     TC1 – TC2
-4.60
21.76
-10.78
1.58
-1.495
0.141
     LDL1–LDL2
-2.30
14.71
-6.48
1.88
-1.106
0.274
     HDL1–HDL2
2.14
7.90
-0.10
4.38
1.916
0.061

T C: Total Cholesterol, LDL: Low Density Lipoprotein Cholesterol, HDL: High Density Lipoprotein Cholesterol, TG: Triglyceride

Kojuri et al. Lipids in Health and Disease 2007 6:5   doi:10.1186/1476-511X-6-5


http://www.biology-online.org/articles/effects_anethum_graveolens_garlic/abstract.html